[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dexamethasone-palmitate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dexamethasone-palmitate":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100619225","dexamethasone-palmitate-for-postoperative-pain-100619225",false,"NCT07341854","Dexamethasone Palmitate for Postoperative Pain","Effect of Intravenous Dexamethasone Palmitate on Postoperative Pain Prevention","Inclusion Criteria:\n\n1. Age 18-65 years.\n2. Scheduled for a range of surgeries under general anesthesia, including both minimally invasive procedures (such as video-assisted thoracoscopic surgery and laparoscopy) and open surgeries (such as thoracotomy, laparotomy, spinal surgery, total joint replacement, and mastectomy).\n3. Capacity to comprehend the study procedures and assessment scales, and communicate effectively with research staff.\n\n4）Classified as American Society of Anesthesiologists (ASA) physical status I, II, or III.\n\n5\\) Willingness to participate voluntarily and provide written informed consent.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to dexamethasone or its excipients.\n2. Systemic glucocorticoid therapy within 3 months prior to enrolment.\n3. History of severe cardiovascular disease, hepatic or renal failure, or systemic rheumatic disease (e.g., rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus).\n4. Coexisting chronic pain at enrolment.\n5. Uncontrolled diabetes mellitus or active systemic infection.\n6. Use of any systemic or topical analgesics within 48 hours prior to surgery.\n7. Significant cognitive impairment or severe psychiatric disorder.\n8. Pregnancy or lactation.","ALL","18 Years","65 Years",{"count":20,"type":21},446,"ESTIMATED","INTERVENTIONAL",[24],"NA","Postoperative pain remains highly prevalent and inadequately managed in a significant proportion of surgical patients, often leading to delayed recovery, increased opioid consumption, and potential progression to chronic pain. While perioperative systemic dexamethasone is used for its anti-inflammatory and opioid-sparing effects, its efficacy is inconsistent, and concerns regarding systemic side effects persist. Dexamethasone palmitate, a novel lipophilic prodrug formulated as nanoparticle emulsion, leverages the enhanced permeability and retention effect to target inflammatory sites selectively, potentially offering superior anti-inflammatory and analgesic efficacy with reduced systemic exposure. This trial aims to evaluate whether preoperative intravenous dexamethasone palmitate is more effective than conventional dexamethasone in preventing moderate-to-severe postoperative pain.",[27,28],"Pain, Postoperative","Dexamethasone Palmitate","NOT_YET_RECRUITING","2026-04-02",{"date":32,"type":33},"2026-04-08","ACTUAL",{"date":35,"type":21},"2026-06-01",{"date":37,"type":21},"2027-12-30",{"name":39,"class":40},"Beijing Tiantan Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100592744","dexamethasone-palmitate-for-ponv-after-open-surgery-100592744","NCT06997419","Dexamethasone Palmitate for PONV After Open Surgery","Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Open Surgery","Inclusion Criteria:\n\n* Aged 18 to 65 years;\n* Providing written informed consent;\n* Perform elective open surgery (Spinal surgery, open chest surgery, open abdominal surgery) undergoing general anesthesia.\n\nExclusion Criteria:\n\n* Known to be allergic to dexamethasone;\n* Any systemic glucocorticoids within 3 months before trial entry;\n* History of severe heart disease, liver\u002Fkidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);\n* Cognitive impairment or severe mental illness;\n* Uncontrolled diabetes or infectious diseases;\n* Pregnancy or breastfeeding.",{"count":50,"type":21},500,[24],"Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after open surgery.",[54,28,55],"Postoperative Nausea and Vomiting","Open Surgery","RECRUITING","2025-09-21",{"date":59,"type":33},"2025-09-23",{"date":61,"type":33},"2025-07-01",{"date":63,"type":21},"2026-12-31",{"name":39,"class":40}]